Authors
No matching authors found
Try adjusting your search criteria
Advertisement
Advertisement
Trending on BioPharm International
1
Immatics’ PRAME-Targeted TCR Bispecific IMA402 Shows 32% Response Rate in PRAME-High Tumors
2
Lilly’s Retatrutide Doubles Ozempic’s Weight Loss in First Phase 3 Head-to-Head Trial
3
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
4
BioMarin Licenses Subcutaneous Fabry ERT From GC Biopharma, Hanmi
5